|
Custom content by studioID
|
|
Approved by the FDA in 2018 for onchocerciasis, moxidectin is now used globally in mass drug administration (MDA) programs. In this webinar, learn how Model-Informed Drug Development (MIDD) ensures the safe use of moxidectin in breastfeeding women, helping address global health disparities.
|
|
|
-
How MIDD supports regulatory and public health decisions.
-
The role of PK and PBPK modeling in evaluating infant exposure
-
How MIDD ensures equitable, data-backed solutions in global health
|
|
This custom content was created by members of the studioID Expert Network for a sponsor of our publication.
|
|
|
studioID is PharmaVoice's award-winning content studio. We help brands tell stories that create connections, build trust, and drive demand. Learn how we can help you tell compelling stories and drive ROI. Visit studioID.com About this email: You are receiving this message as part of your complimentary newsletter subscription to PharmaVoice. If you no longer wish to receive the daily newsletter, you can switch to a weekly subscription or unsubscribe. See our full privacy policy. PharmaVoice is a product of Industry Dive, Inc. 1255 23rd Street NW, Suite 550 Washington DC 20037
|
|
|
|
